All ESA Annual Meeting proposal and abstract deadlines are 5:00 PM Eastern so that technical support and ESA staff assistance will be immediately available when submitters need it. If you begin your ...
PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will ...
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced an oral ...
BALLERUP, Denmark--(BUSINESS WIRE)--NOT FOR UK USE – NOT INTENDED FOR UK MEDIA LEO Pharma A/S, a global leader in medical dermatology, will present new clinical and real-world data from across its ...
The MarketWatch News Department was not involved in the creation of this content. Poster Presentation on VENTURE Study Results Evaluating Impact of VK2735 on Prediabetes and Cardiometabolic Status ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (”Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the ...
The following is a list of the presenters who will have a poster at the NAWEA/WindTech 2023 Conference on the evening of Monday, Oct. 30, 2023. See the program schedule and speaker schedules.
Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented One presentation will summarize results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback